JP7583022B2 - 呼吸器症状の治療における使用のためのｔｍｅｍ１６ａモジュレータとしてのピリジン誘導体 - Google Patents

呼吸器症状の治療における使用のためのｔｍｅｍ１６ａモジュレータとしてのピリジン誘導体 Download PDF

Info

Publication number
JP7583022B2
JP7583022B2 JP2022504089A JP2022504089A JP7583022B2 JP 7583022 B2 JP7583022 B2 JP 7583022B2 JP 2022504089 A JP2022504089 A JP 2022504089A JP 2022504089 A JP2022504089 A JP 2022504089A JP 7583022 B2 JP7583022 B2 JP 7583022B2
Authority
JP
Japan
Prior art keywords
hydroxy
amino
pyridine
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022504089A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021014166A5 (enExample
JP2022541311A (ja
Inventor
スティーブン コリングウッド，
クレイグ バクストン，
ジョナサン デーヴィッド ハーグレイヴ，
ピーター イングラム，
トーマス ボーレガード ショーフィールド，
アブドル シェーク，
クリストファー スティムソン，
Original Assignee
ティエムイーエム１６エー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910607.9A external-priority patent/GB201910607D0/en
Priority claimed from GBGB2005739.4A external-priority patent/GB202005739D0/en
Application filed by ティエムイーエム１６エー リミテッド filed Critical ティエムイーエム１６エー リミテッド
Publication of JP2022541311A publication Critical patent/JP2022541311A/ja
Publication of JPWO2021014166A5 publication Critical patent/JPWO2021014166A5/ja
Application granted granted Critical
Publication of JP7583022B2 publication Critical patent/JP7583022B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2022504089A 2019-07-24 2020-07-24 呼吸器症状の治療における使用のためのｔｍｅｍ１６ａモジュレータとしてのピリジン誘導体 Active JP7583022B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1910607.9A GB201910607D0 (en) 2019-07-24 2019-07-24 Compounds
GB1910607.9 2019-07-24
GB2005739.4 2020-04-20
GBGB2005739.4A GB202005739D0 (en) 2020-04-20 2020-04-20 Compounds
PCT/GB2020/051778 WO2021014166A1 (en) 2019-07-24 2020-07-24 Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions

Publications (3)

Publication Number Publication Date
JP2022541311A JP2022541311A (ja) 2022-09-22
JPWO2021014166A5 JPWO2021014166A5 (enExample) 2023-07-25
JP7583022B2 true JP7583022B2 (ja) 2024-11-13

Family

ID=71948615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504089A Active JP7583022B2 (ja) 2019-07-24 2020-07-24 呼吸器症状の治療における使用のためのｔｍｅｍ１６ａモジュレータとしてのピリジン誘導体

Country Status (16)

Country Link
US (1) US20220235006A1 (enExample)
EP (1) EP4003516A1 (enExample)
JP (1) JP7583022B2 (enExample)
KR (1) KR20220063162A (enExample)
CN (1) CN114616226B (enExample)
AU (1) AU2020317036A1 (enExample)
BR (1) BR112022001164A2 (enExample)
CA (1) CA3145120A1 (enExample)
CL (1) CL2022000147A1 (enExample)
CO (1) CO2022002022A2 (enExample)
CR (1) CR20220072A (enExample)
IL (1) IL290035A (enExample)
MX (1) MX2022000841A (enExample)
PE (1) PE20221441A1 (enExample)
PH (1) PH12022550181A1 (enExample)
WO (1) WO2021014166A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221441A1 (es) * 2019-07-24 2022-09-21 Tmem16A Ltd Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
KR20260025059A (ko) * 2024-08-13 2026-02-23 전남대학교산학협력단 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042524A1 (en) 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase
WO2018195127A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Substituted 2-acylamino-cycloakylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
WO2019145726A1 (en) 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221441A1 (es) * 2019-07-24 2022-09-21 Tmem16A Ltd Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042524A1 (en) 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase
WO2018195127A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Substituted 2-acylamino-cycloakylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
WO2019145726A1 (en) 2018-01-26 2019-08-01 Enterprise Therapeutics Limited Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAMKUNG, Wan et al.，TMEM16A InhibitorsReveal TMEM16A as a Minor Componentof Calcium-activated Chloride ChannelConductance in Airway and Intestinal Epithelial Cells，THE JOURNAL OFBIOLOGICAL CHEMISTRY，2011年，VOL.286, NO.3，pp.2365-2374，DOI:10.1074/jbc.M110.175109

Also Published As

Publication number Publication date
CR20220072A (es) 2022-06-29
MX2022000841A (es) 2022-06-08
WO2021014166A1 (en) 2021-01-28
CL2022000147A1 (es) 2022-10-07
PE20221441A1 (es) 2022-09-21
JP2022541311A (ja) 2022-09-22
PH12022550181A1 (en) 2023-01-16
KR20220063162A (ko) 2022-05-17
IL290035A (en) 2022-03-01
CO2022002022A2 (es) 2022-06-10
CA3145120A1 (en) 2021-01-28
US20220235006A1 (en) 2022-07-28
AU2020317036A1 (en) 2022-03-17
CN114616226A (zh) 2022-06-10
CN114616226B (zh) 2025-03-04
EP4003516A1 (en) 2022-06-01
BR112022001164A2 (pt) 2022-03-15

Similar Documents

Publication Publication Date Title
US11364246B2 (en) Compounds
CN104968656A (zh) 自分泌运动因子抑制剂
JP7583022B2 (ja) 呼吸器症状の治療における使用のためのｔｍｅｍ１６ａモジュレータとしてのピリジン誘導体
US20200361871A1 (en) Compounds
US12552770B2 (en) Compounds for treating respiratory disease
WO2020249956A9 (en) Modulators of tmem16a for treating respiratory disease
JP7682850B2 (ja) カルシウム活性化クロライドチャネルモジュレーターとしてのピリジン誘導体
HK40069002A (en) Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
HK40075169A (en) Pyridine derivatives as calcium-activated chloride channel modulators
JP2023552638A (ja) 呼吸器疾患を治療するためのベンゾイミダゾール誘導体
HK40067764A (en) Compounds for treating respiratory disease
HK40075169B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
HK40067765A (en) Modulators of tmem16a for treating respiratory disease
HK40042091B (en) Tmem16a modulators
HK40042091A (en) Tmem16a modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241031

R150 Certificate of patent or registration of utility model

Ref document number: 7583022

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150